Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer
Background and objective Erlotinib has been approved worldwide for second- and third-line treatment of advanced NSCLC. Clinical trials showed that patients with EGFR mutations treated with erlotinib has better clinical outcomes. The aim of this study is to evaluate the effects of erlotinib monothera...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Chinês |
| Cyhoeddwyd: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2009-12-01
|
| Cyfres: | Chinese Journal of Lung Cancer |
| Pynciau: | |
| Mynediad Ar-lein: | http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.12.03&path[]=1227 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|